CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Blue Light Cystoscopy in Patients with Suspected Non-Muscle Invasive Bladder Carcinoma: A Review of Clinical Utility

Last updated: February 15, 2017
Project Number: RC0848-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the clinical utility of blue light cystoscopy in patients with suspected NMIBC undergoing TURBT?

Key Message

Hexaminolevulinate-guided transurethral resection of bladder tumors was associated with a decreased risk of bladder cancer recurrence and a decreased risk of progression to muscle invasive bladder cancer compared to white light cystoscopy. Evidence on mortality and harms was inconclusive due to sparse data.